+ Watch AGEN
on My Watchlist
A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches.
0.9 has been a relatively stable floor for Agenus over the last eight months. Potential positive catalysts include presentation of data from phase II trial of Prophage G-200 in glioma and results of several phase III vaccine trials by collaborators using the QS-21 adjuvant. The absence of revenues resulting from Russian approval of Oncophage seems to be a forgotten issue.I still believe that Agenus's immunotherapy pipeline isn't much more than a scam. On the other hand, their vaccine adjuvant seems to have attracted some fairly deep-pocketed collaborators. At this price and in a simulated situation, Agenus gets the benefit of the doubt for now.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions